Loading...
Loading...
CTXR| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 47.2K |
| Gross Profit | -47.2K |
| Operating Expense | 7,249.9K |
| Operating I/L | -7,249.9K |
| Other Income/Expense | 3,800.2K |
| Interest Income | 214.5K |
| Pretax | -3,449.6K |
| Income Tax Expense | 144.0K |
| Net Income/Loss | -3,593.6K |
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing critical care products, including anti-infective products for adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company's proprietary products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite, and I/ONTAK, targeting catheter-related bloodstream infections, tissue expander infections, hemorrhoids, acute respiratory disease syndrome, and cutaneous T-cell lymphoma. By developing and marketing these innovative medical solutions, Citius Pharmaceuticals generates revenue through the sale and distribution of its pharmaceutical products, catering to the needs of patients and healthcare providers in the critical care space.
